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Heart failureAbstract It has been shown that patients with heart failure have high levels of brain or type B
natriuretic peptide (BNP), and that there is a correlation between these and the severity of their con-
dition. Many studies report that monitoring BNP levels could be a sensitive method for diagnosing
heart failure and performing risk stratiﬁcation, and that they could act as an independent predictor
of adverse events helping clinicians arrive at a prognosis.
To achieve this purpose we studied 30 patients with CHF (27 males, mean age 57 years) under-
going CRT implantation.
The main ﬁnding of our study was that CRT exerted a substantial reduction in plasma BNP levels
among responders, but no signiﬁcant change in nonresponders after 3 months follow-up, only
responders showed a signiﬁcant decrease in plasma BNP levels (229.64 pg/ml ± 111) as compared
to non-responders (468 pg/ml ± 96) P value <0.01. Response could be predicted with a cut-off
value of 360 pg/ml, with a sensitivity and speciﬁcity of 90.9% and 87.5%, respectively.
In conclusion, BNP monitoring is potentially a good prognostic indicator of LV functional recov-
ery and reverse remodeling after CRT can accurately identify echocardiographic responders after
CRT. Percentage change in plasma BNP levels from baseline to 3 months was the strongest predic-
tor of long-term response to CRT and may have potential to predict outcome.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiac resynchronization therapy (CRT) is an established
therapy for patients with moderate-to-severe heart failure
(HF) and ventricular dyssynchrony. CRT improves Cardiac
function, quality of life (QoL), and life expectancy in patients
with HF [1–4]. Biventricular pacing improves symptoms (New
York Heart Association [NYHA] class), exercise tolerance
(6-min walk distance), and quality-of-life scores by decreas-
ing dyssynchrony in patients with advanced chronic HF
[5–7]. Cardiac resynchronization therapy (CRT) optimizes
ventricular loading conditions, improves systolic function,
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remodeling [5,6,8].
However, lack of response to CRT has been reported in up
to 30% of patients [6,8,9]. On the basis of these considerations,
a variety of parameters, including echocardiographic ventricu-
lar dyssynchrony [10], QRS reduction after implantation [11],
and the location and extent of myocardial scarring [12], have
been reported to be predictors of the response to CRT, but dis-
appointing results from PROSPECT study indicated the limi-
tation of these parameters [13].
There has been growing interest in identifying new markers
for dyssynchrony and the techniques to optimize device set-
tings to increase the true-responder rate, in addition to optimal
medical management [14–17]. CRT-induced reverse remodel-
ing could reduce neurohormonal activity in addition to
improving anatomic and functional parameters.
Brain natriuretic peptides (BNP) and its inactive amino ter-
minal portion (NT-pro BNP), are neurohormones released by
the ventricle in response to increase LV wall stress. Hence,
BNP level may play a valuable role for the assessment of car-
diac dysfunction, particularly LV dysfunction, and for moni-
toring of the response to cardiac therapy [18,19]. Decrease in
BNP associated with drug treatment in patients with CHF cor-
relates with improvement in hemodynamic parameters [20–22],
clinical status and prognosis, including number of hospitaliza-
tions for deterioration of CHF [23,24]. Fruhwald et al. [25]
showed that CRT leads to an early and sustained decrease in
NT-pro BNP potentially reﬂecting improvement in LV func-
tion. In responders, left lateral wall pacing increases systolic
function, reduces mitral regurgitation (MR) and thus decrease
the wall motion stress. In this favorable remodeling process,
neurohumoral activity is reduced and the decrease in plasma
B-type natriuretic peptide after initiation of CRT predicts clin-
ical improvement during follow-up [26].
1.1. Aim of work
The aim of this study was to evaluate the effect of CRT on
plasma concentrations of b-type natriuretic peptide (BNP)
and the value of BNP in predicting the clinical response to
CRT.2. Patients and methods
Over a period of one year from September 2012 to November
2013, thirty patients who received a biventricular pacing sys-
tem were studied. They included 27 males and 3 females, with
a mean age of 57.5 ± 6 years.
The patients were studied at the (Critical care department)
Cairo University.
2.1. Inclusion criteria
 Advanced CHF (NYHA class II-IV) despite optimized
drug therapy including angiotensin converting enzyme
inhibitors or Angiotensin receptor antagonists, diuretics,
beta-receptor blockers and spironolactone when
tolerated. Intraventricular conduction delay (QRSP 120 ms) in the
form of left bundle branch block.
 Left ventricular ejection fraction (LVEF) 635% as assessed
by echocardiography.
2.2. Exclusion criteria
(1) Patients with uncontrolled HF requiring hospital admission
or not on stable medical therapy for the last three months; (2)
serum creatinine level P2 mg/dl; (3) myocardial infarction
within previous 3 months; (4) previous valve replacement or
reconstructions.
2.2.1. The studied patients were subjected to baseline assessment
including
Informed written consent, Full history taking and clinical
examination, twelve lead ECG, NYHA class, blood pressure,
heart rate, CHF compensation status and QRS duration were
assessed during each clinical follow-up visit, and their exercise
capacity was assessed by a 6-min walk test.
2.3. All patients were subjected to
2.3.1. Biochemical assays
BNP level was assessed in the absence of uncontrolled HF one
to 10 days before implantation. Blood samples were drawn
from an antecubital vein in the morning before and 3 months
after the implant. Blood for measurement of plasma BNP was
transferred to a chilled tube containing ethylenediaminete-
traacetic acid (EDTA) (1 mg/ml) and aprotinin (500 kallikrein
inactivator U/mL). Test tubes were immediately centrifuged.
Plasma samples were stored at 70 C until assay. Plasma
BNP concentrations were measured using a speciﬁc immuno-
radiometric assay (non-extracted) for human BNP. (RayBio,
USA) done at our unit Lab. The analysis was blind to the
outcome.
2.3.2. Echocardiographic measurements
All patients were subjected to transthoracic echocardiographic
examination using ATL.HDI 5000 colored echocardiographic
machine using a 3.5 MHz transducer (PHILIPS).
Two-dimensional Doppler-ﬂow echocardiography was per-
formed at baseline and at follow up to assess left ventricular
(LV) ejection fraction (EA), diastolic dimensions and the
degree of mitral regurgitation quantiﬁcation (from grade 1 to
4). LVEF was calculated using the single plane method. The
analysis was blinded to the outcome.
2.4. Study protocol
Peripheral blood samples for analysis of BNP were drawn at
baseline and 3 months after initiation of CRT. At baseline,
history, clinical status, drug therapy, echocardiographic
parameters and Exercise capacity testing were evaluated.
Three months after implantation of the CRT system, clinical
status, drug therapy and echocardiographic data were
assessed.
Table 1 Baseline data.
Age (yrs) 57.5 ± 6
Men 27
NYHA class (II/III/IV) 2/23/5
LVEF (%) 28.83 ± 4.46
LVEDD (mm) 299.53 ± 41.64
LVESV (mm) 209.5 ± 36.6
Mitral regegurge (mild/moderate/severe) 11/13/6
PM dependency 2
CRT-p/CRT-D 28/2
Ischemic cardiomyopathy 17
Preimplantation QRS(ms) 149 ± 15.17
BNP level (pg./ml) 449.73 ± 86.03
ACEI/ARBs 28
B blockers 21
Diuretics 26
Spironolactone 20
Digoxin 7
6MWT 311 ± 31 m
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Figure 1 Presence of ischemic heart disease (IHD). As shown in
the ﬁgure there was no signiﬁcant difference in the number of
patients having IHD in the study population.
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2.5.1. Clinical criteria
 >1 point decrease in NYHA functional class [27,28].
2.5.2. Echocardiographic criteria
 A reduction of LVESV by 15% or greater after CRT
[13,29,30].
2.6. Statistical analysis
Quantitative variables are expressed as mean value ± SD,
whereas qualitative variables are expressed as number and per-
centage. Descriptive analysis was performed for all relevant
continuous variables. Comparison between groups was done
using chi-square for qualitative variables & independent sam-
ples, T-test for normally distributed quantitative variables.
Quantitative variables not normally distributed were com-
pared using non-parametrical Mann–Whitney test & Krus-
kal–Wallis Test. Logistic regression analysis was used to
examine the predictors of responders for CRT. To evaluate
the predictive value of changes in plasma BNP levels, receiver
operating characteristic (ROC) analysis was performed, the
area under the curve (AUC) calculated and possible cut off
points were selected. Statistical signiﬁcance was set at
P< 0.05. All data were analyzed using the SPSS v. 12.0 statis-
tical packages.
3. Results
3.1. Demographic data
Age of patients undergoing the study ranged from 42 to
70 years with a mean of 57.5 ± 6.6 years, (90%) were males
and 3 (10%) were females (Table 1).
3.1.1. Clinical presentation
3.1.1.1. Underlying heart disease causing heart failure. Of the
study group 17 patients (56.7%) had Ischemic heart disease,
while 13 (43.3%) were non-ischemic (Fig. 1).
3.1.1.2. NYHA class before PM implantation. Prior to implan-
tation 23 patients (76%) had NYHA class III while 2 patients
(6%) had NYHA class II and 5 patients had ambulatory
NYHA class IV (16%).
3.1.1.3. Type of pacemaker implanted. Twenty-eight patients
(93.3%) had received a CRT-P System, whereas 2 patients
(6.7%) had a CRT-D (see Table 2).
3.1.2. CRT response
Among the 30 patients included in this study, 22 (73.3%) were
considered Responders to CRT (see Fig. 2).
3.1.2.1. Baseline echocardiographic parameters. Baseline LV
volumes and LVEF, were not signiﬁcantly different between
responders and non-responders (see Fig. 4).3.1.2.2. Underlying cause for heart failure. There was no statis-
tical difference regarding etiology of heart failure between the
two groups (p value = 0.407) (see Fig. 3).
3.1.2.3. Baseline QRS width. As seen in the only baseline
parameter that was highly signiﬁcant between Responders
and non-Responders prior to CRT implantation was QRS
width in surface ECG. The Baseline QRS width ranged
between 130–170 ms with a mean of 143 ± 12 in responders,
and ranged between 150–180 ms. in non-responders mean
165 ± 10.69) P value was <0.001.
3.1.3. BNP at baseline and after follow-up
At Baseline the mean BNP level was 464.55 ± 80 pg/ml in
Responders and 409 ± 94 pg/ml in Non-Responders with no
statistical difference between the two groups (p value 0.120).
However at follow up, only the Responders showed a sig-
niﬁcant decrease in plasma BNP levels (229.64 pg/ml ± 111)
as compared to Non-Responders (468 pg/ml ± 96), P
value < 0.001.
Table 2 Baseline parameters.
Responders Non-responders P value
Baseline LV parameters
EDV (mm) 298 ± 42 301 ± 42 0.86
ESV (mm) 209 ± 36 217 ± 40 0.625
EF (%) 29 ± 4 27 ± 4 0.38
Heart failure etiology 0.407
Ischemic 11 6
Non-ischemic 11 2
QRS width (ms) 143 ± 12 165 ± 11 <0.001
BNP level (pg/ml) 464 ± 80 409 ± 94 0.120
Total 22 8
Figure 3 Correlation between changes in LVEDV and plasma
levels of BNP at followup (r= 0.75, p< 0.001).
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in differentiating responders and non-responders, ROC curve
and AUC parameters were analyzed.
 Percent change in BNP (DBNP%) was associated with the
largest AUC (1.000, 95% conﬁdence interval 0.883–1), fol-
lowed by absolute change in BNP (BNP pg/ml)
(AUC= 0.943, 95% conﬁdence interval 0.793–0.992). A
drop in DBNP% of more than 4.615% differentiated
responders from non-responders with 100% sensitivity
and 100% speciﬁcity.
 A cut-off BNP value of 360 pg/ml had a speciﬁcity of 87.5%
and a sensitivity of 90.9% in predicting CRT response.
3.1.4. Improvement in echo parameters at follow-up
A statistically signiﬁcant decrease in left ventricular volumes
LVEDV (298.6 ± 42 ml vs. 243.3 ± 37 ml p< 0.001) and
LVESV (209.5 ± 36 ml vs. 149 ± 28 ml, p< 0.001), together
with an improvement in LVEF (29 ± 4% vs. 38 ± 4%,
p< 0.001).
3.1.5. QRS width
As seen in Table 3 the mean QRS width decreased at follow up
mainly among the Responders.BNP_after
0 20 40 60 80 10
100
80
60
40
20
0
100-Specificity
Se
ns
iti
vi
ty
 Sensitivity: 90.9
 Specificity: 87.5
 Criterion : <=360
Figure 2 ROC curve showin3.1.6. Correlation between BNP level and LV volumes and
ejection fraction at follow-up
The change in BNP level at follow up had high negative corre-
lation with the change in LVEF (r= 0.7194, P< 0.001) and
a high positive correlation with LV end-diastolic volume
(r= 0.7504, P< 0.001) and LV end-systolic volume
(r= 0.74360.45, P< 0.001).
3.1.7. Correlation between change of BNP level and change of
6 min walk test at follow up
The plasma BNP levels at follow up also showed high negative
correlation with the 6 min walk test at follow up r= 0.681
with p value <0.001.0
Area under the ROC 
curve (AUC)  
0.943 
Standard Error  0.0594 
95% Confidence Interval  0.793 to 0.992 
z statistic  7.467 
Significance level P 
(Area=0.5) 
0.0001 
g BNP level at follow-up.
Figure 4 Correlation between changes in LVEF and plasma
levels BNP at follow-up (r= 0.74, p< 0.001).
Table 3 Follow-up parameters among responders and non-
responders.
Responders Non-responders P value
LV parameters
EDV (mm) 243 ± 37 299 ± 42 <0.001
ESV (mm) 149 ± 28 219 ± 39 <0.001
EF (%) 38 ± 4 27 ± 4 <0.001
QRS width (ms) 100 ± 14 131 ± 17 <0.001
BNP level (pg/ml) 229 ± 111 468 ± 96 <0.001
Total 22 8
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3.1.8.1. LV volumes and ejection fraction. There was high pos-
itive correlation between QRS width in surface ECG at follow
up with both LV volumes (EDV, ESV) r= 0.473 and 0.616
and negative correlation with EF r= 0.687 with p-
value < 0.001.Table 4 Comparison between the previous studies and the current
Author Year No. of
patients
Baseline BNP
Filzmaier
et al.
2002 12 537 ± 306 pg/ml
Sinha
et al.
2003 17 700 ± 33 pg/ml
Mortada
et al.
2005 32 984 ± 38 pg/ml
Civello
et al.
2005 37 Mean 569 pg/ml in responders
Mean 624 pg/ml in non-responders
Kubanek
et al.
2006 43 BNP345.3 ± 34 pg/ml big ET1-1 3.11
± 1.50 fmol/ml
Fruhwald
et al.
2007 813 Median plasma con. of NT-pro-BNP
1920 pg/mL
Our study 2015 30 BNP was 449 ± 94 pg/ml in responders
and 464 ± 94 in non-responders3.1.8.2. 6 min walk test. The QRS width at follow up had a neg-
ative correlation with the 6 min walk test at follow up
r= 0.68132 with p value <0.001 (see Table 4).
4. Discussion
Landmark clinical trials such as COMPANION [9] and
CARE-HF [10] have shown a survival beneﬁt with CRT. This
therapy has opened up a whole new modality in the treatment
of HF, focusing on electromechanical assistance to the failing
heart.
Although the clinical results of CRT are promising, analysis
of individual responses has revealed that almost 30% of
patients do not exhibit any symptomatic or hemodynamic
improvement: the so-called non-responders [31–33]. One of
the reasons for this may be suboptimal programing of the
device, which has particular considerations as compared to
standard pacemakers [34].
Plasma B-type natriuretic peptide (BNP) is a very useful
diagnostic and prognostic marker in stratifying HF patients
and guiding optimization of HF treatment. BNP levels corre-
late well with functional class and hemodynamics and is an
independent prognostic indicator in patients with congestive
HF, however, the predictive role of preimplantation BNP
determination remains unclear [35,36].
5. Main finding
The main ﬁnding of our study was that CRT exerted a sub-
stantial reduction in plasma BNP levels in responders, but
no signiﬁcant change in non-responders after 3 months
follow-up and that change in plasma BNP level between base-
line and 3 months after CRT may be useful to identify
echocardiographic responders following CRT.
Filzmaier et al. [37] showed signiﬁcant reductions in BNP
levels after only 4–6 days of continuous biventricular pacing.
Mortada et al. [38] noted signiﬁcant reductions (P< 0.05) in
plasma BNP levels from baseline to 3-month follow-up in
87% of their study participants.
Sinha et al. [39] in 2003 documented signiﬁcant reductions
in BNP levels associated with signiﬁcant reductions in LV vol-cohort.
Results
Reduction of BNP levels to 255 ± 200 pg/ml
p< .001
BNP decreased to 503 ± 31 pg/ml after reinitiating CRT therapy
p< 0.01
Reduction in plasma BNP levels in 28 (87%) patients
184 ± 45 pg/ml, p< 0.5
Responders had a delta BNP of 240 ± 66 pg/ml and non-
responders had a delta BNP of 16 ± 89 ml (p< 0.01)
Reduction in neurohormone levels BNP 267.7 ± 320.8 pg/ml,
p< 0.01, big ET-1 2.50 ± 1.56 fmol/ml p< 0.05
The diﬀerences in medians at 18 months of follow-up (567 pg/mL
P< 0.0001)
BNP 229 ± 111 in responders and 468 ± 96 in non-responders
p< 0.01
102 A. Nawar et al.ume and a signiﬁcant increase in ejection fraction, which
remained consistent throughout long-term follow-up
(>1 year) in patients treated with biventricular pacing.
Fruhwald et al. [25] in 2007 in a study on patients with
moderate or severe HF and LV dyssynchrony showed that
CRT exerts an early and sustained reduction in BNP level
reﬂecting the improvements in LV geometry and function.
Moreover, the Care-HF post-hoc analysis concluded that
BNP may be used to monitor CRT effect [40].
Indeed, response to CRT is clearly a multifactorial process
including the severity of intraventricular asynchrony, presence
and localization of LV viability and lead placement with
respect to the latest LV activation site. In contrast, BNP
release is essentially determined by LV wall stress. Hence, it
is not surprising that baseline BNP is not accurate to predict
clinical or echocardiographic response after CRT [41].
5.1. LV remodeling
Furthermore, our results showed that BNP is also a good sur-
rogate marker to identify LV remodeling following CRT as it
showed strong correlations with both LV volumes; LVEDV
(r= 0.7504, P< 0.001), LVESV (r= 0.74360.45,
P< 0.001) and LVEF (r= 0.7194, P< 0.001). More
importantly, BNP monitoring allows the clinician to accu-
rately identify echocardiographic responders to CRT. Since
LV remodeling predicts outcome with better accuracy than
clinical improvement after CRT and that BNP monitoring
can identify echocardiographic responders with a very good
sensitivity and speciﬁcity, assessment of BNP after CRT could
be used as an additional tool to assist the clinician in the eval-
uation of the patient’s condition [42].
After adjusting for all variables, neither echo parameters (p
value was 0.865, 0.495, and 0.380 for EDV, ESV and EF
respectively), nor BNP level (p value 0.120) prior to implanta-
tion could predict responders. Only QRS width in surface
ECG could predict responders (p=<0.01). A cut-off QRS
width of 140 ms had a speciﬁcity of 100% and a sensitivity
of 59.1% in predicting CRT response.
5.2. Practical implications
Our results may have important implications for management
decisions in patients receiving CRT. The long term outcome of
CRT could be predicted by changes in BNP level earlier after
implant of the CRT system (i.e. after three months). This is
supported by the fact that patients at high risk of heart failure
progression should be followed more closely and receive more
aggressive clinical management, including programing of tim-
ing intervals and basic heart rate, ﬁne tuning pacing mode
[43] and more aggressive therapeutic strategies.
Furthermore, our study may provide an easy yet reliable
surrogate marker to deﬁne CRT response. Previous studies
use different deﬁnitions of CRT response varying from func-
tional parameters (such as NYHA class, 6 min walking test)
to reverse LV Remodeling and/or toward morbidity and mor-
tality [44]. The property of BNP to deﬁne the CRT response is
related to the fact that the peptide reﬂects the complex func-
tional and anatomical status of the cardiovascular system as
a whole and may therefore be a more sensitive parameter of
clinical status.The study is limited however by the relatively small study
group, larger studies are needed to further support these
ﬁndings.
6. Conclusions
 BNP monitoring is potentially a good prognostic indicator
of LV functional recovery and reverse remodeling after
CRT, and can accurately identify echocardiographic
responders after CRT. The ﬁndings though are limited to
this cohort study.
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